Cytiva expands Fast Trak™ process development and validation services facility in India

New Delhi: Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru, India.

The center will help biopharma companies in India and across Asia-Pacific shorten development timelines, reduce manufacturing risk, and scale confidently—as India aims to grow its bioeconomy to USD 300 billion by 2030.

The ~30 000 ft2 facility brings together upstream and downstream process development, optimization and scale-up, and validation services under one roof. It also offers immersive training to provide customers with the knowledge and skills to accelerate their molecule-to-market journey.

Pierre-Alain Ruffieux, Chief Operating Officer, Cytiva, says: “India’s scientific strength plays a vital role in global biopharma, and this facility reinforces that momentum. By expanding our capabilities here, we’re giving customers the infrastructure to move from idea to impact with greater speed, reliability, and excellence.”

Manoj Panicker, General Manager, Cytiva South Asia, says: “This facility will enable our customers to innovate faster while maintaining complete control of their processes—improving access to life-saving medicines. This is especially critical for rare diseases, emerging modalities, and the growing biosimilars market, where speed and flexibility are essential.”

Building bioprocessing strength for India and the world

According to Cytiva’s 2025 Biopharma Index, 56% of global biopharma executives agree that domestic manufacturing of biologics is set to increase dramatically over the next three years. This is especially apparent in India, where demand for biologics and biosimilars is rising and customers increasingly need localized expertise with global quality standards.

Deployed in a GLP-compliant biosafety level 2 (BSL-2) environment, Cytiva’s PD solutions at Fast Trak India are designed for single‑use bioreactor scale up to 200L and can produce toxicity batch material to support preclinical stages. The ISO‑certified validation lab provides specialized testing and documentation services for sterilizing grade filters and single-use system needs.

By offering comprehensive services aligned to sustainability best practices, Cytiva empowers customers to increase yield, improve product quality, reduce manufacturing time and cost, and ensure regulatory compliance. This integrated approach gives biotechs access to infrastructure and expertise that enables faster progress from early development to commercialization in a rapidly evolving biopharma landscape.

Cytiva and the drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.